Knoll Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Knoll Capital Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-200,000	Closed	-$1.42M	–	17
2017 Q3	$1.42M	Hold	200,000	–	–	1.21%	8
2017 Q2	$1.45M	Hold	200,000	–	–	1.92%	7
2017 Q1	$1.23M	Hold	200,000	–	–	1.86%	10
2016 Q4	$1.17M	Hold	200,000	–	–	2.06%	11
2016 Q3	$1.03M	Hold	200,000	–	–	1.81%	12
2016 Q2	$1.32M	Hold	200,000	–	–	0.43%	11
2016 Q1	$934K	Hold	200,000	–	–	0.38%	12
2015 Q4	$1.01M	Hold	200,000	–	–	0.37%	13
2015 Q3	$704K	Hold	200,000	–	–	0.3%	13
2015 Q2	$2M	Hold	200,000	–	–	0.64%	10
2015 Q1	$2.55M	Hold	200,000	–	–	0.74%	7
2014 Q4	$2.83M	Hold	200,000	–	–	1.11%	6
2014 Q3	$2.75M	Hold	200,000	–	–	1.07%	4
2014 Q2	$3.08M	Hold	200,000	–	–	1.37%	4
2014 Q1	$3.41M	Hold	200,000	–	–	1.76%	5
2013 Q4	$2.59M	Buy	200,000 +100,000	+100%	+$1.19M	1.31%	4
2013 Q3	$1.01M	Hold	100,000	–	–	0.54%	8
2013 Q2	$747K	Buy	+100,000	New	+$781K	0.51%	8

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Knoll Capital Management's KERX Position: Q4 2017 in Review

Knoll Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 200,000 shares — an estimated $1.42M sold.

Knoll Capital Management first reported a position in KERX in Q2 2013 and held it in 18 quarters. The position peaked at $3.41M in Q1 2014. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

Knoll Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Knoll Capital Management sold 200,000 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $1.42M.
Knoll Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
Knoll Capital Management's Keryx Biopharmaceuticals Inc position peaked at $3.41M in Q1 2014.
129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Knoll Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.